Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2011Cancer ResearchOpen Access

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

TSTakaaki SasakiAsahikawa Medical College HospitalJKJussi KoivunenOulu University HospitalAOAtsuko OginoMerck & Co., Inc., Rahway, NJ, USA (United States)

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sasaki et al. (2011) studied this question.

synapsesocial.com/papers/6a7078bf2163a0a01bc4b01ahttps://doi.org/10.1158/0008-5472.can-11-1340
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK2011 · 544 citations
  2. 2The Neuroblastoma-Associated F1174L ALK Mutation Causes Resistance to an ALK Kinase Inhibitor in ALK-Translocated Cancers2010 · 334 citations
  3. 3Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia2010 · 1,692 citations
  4. 4Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification2001 · 3,123 citations
  5. 5Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer2010 · 4,508 citations